UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $6.5
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and lowers the price target from $8.6 to $6.5.
UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and lowers the price target from $8.6 to $6.5.